Breaking News, Trials & Filings

FDA Approves Allergan’s UBRELVY

Represents the first and only orally-administered CGRP receptor antagonist for the treatment of migraine

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan received approval from the U.S. FDA for UBRELVY (ubrogepant) for the acute treatment of migraine with or without aura in adults. UBRELVY is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start. Migraine is a neurological disease characterized by intermittent migraine attacks with symptoms that are often incapacitating. Migraine afflicts 31 million Americans and is the third most c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters